off label semaglutide Off-label prescription of diabetes drug causes shortage | Industry news FDA warns dangers of using

Potential long-term outcomes: chronic gastroparesis intestinal dysmotility persistent nausea and vomiting lifelong dietary dependence gastric emptying permanently slowed Some patients report non-reversible gastroparesis even after stopping the drug

Once-weekly injection options Wegovy evaluation when appropriate Starting-dose and maintenance monitoring Insurance and self-pay pathways Tirzepatide and Zepbound Evaluation Tirzepatide acts at both GIP and GLP-1 receptors

Fibroblasts respond to the peptide by increasing collagen type I deposition

doi: 10.1093/rheumatology/kep287 66 GladmanDNashPGotoHBirtJLinC-YOrbaiA-Met al